|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2002-7-24
|
|
pubmed:abstractText |
To determine the maximum tolerated dose (MTD) of weekly gemcitabine plus docetaxel, a dose escalation trial of both drugs was developed with each administered weekly for 3 weeks out of 4.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0030-2414
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2002 S. Karger AG, Basel
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
62
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
299-304
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12138236-Adult,
pubmed-meshheading:12138236-Aged,
pubmed-meshheading:12138236-Aged, 80 and over,
pubmed-meshheading:12138236-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12138236-Deoxycytidine,
pubmed-meshheading:12138236-Female,
pubmed-meshheading:12138236-Humans,
pubmed-meshheading:12138236-Male,
pubmed-meshheading:12138236-Maximum Tolerated Dose,
pubmed-meshheading:12138236-Middle Aged,
pubmed-meshheading:12138236-Neoplasms,
pubmed-meshheading:12138236-Neutropenia,
pubmed-meshheading:12138236-Paclitaxel,
pubmed-meshheading:12138236-Taxoids,
pubmed-meshheading:12138236-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study.
|
|
pubmed:affiliation |
Department of Medicine, Division of Hematology/Oncology, Indiana University and The Walther Cancer Institute, Indianapolis, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
